Adenoviral Vectors for Gene Therapy
- 3rd Edition - April 9, 2025
- Editors: David T. Curiel, Alan L. Parker
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 8 2 1 - 8
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 8 1 4 - 1
Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, as platforms for gene therapy and gene editing, as well as for oncology approaches, making them class leading agents in the gene-advanced therapies arena.
The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
- Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors
- Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement
- Demonstrates noninvasive imaging of adenovirus-mediated gene transfer
- Discusses the utility of adenoviral vectors in animal disease models
- Considers Food and Drug Administration regulations for human clinical trials
Researchers in virology, genetics (specifically gene therapy) and others engaged in therapeutics research; "translational" physician-scientists will find this a unique resource for understanding the clinical issues of applying adenoviral vectors
1. Structural Biology of Adenovirus
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Adenoviral Vector Packing Cell Lines
7. Purification of Adenovirus
8. Innate Immune Response to Adenovirus
9. Antibodies to Adenovirus
10. Methods to Mitigate Immune Response
11. Xenogenic Adenoviral Vectors as Vaccines
12. Adenoviral Vector Targeting
13. Helper-Dependent Adenovirus
14. Hybrid Adenoviral Vectors
15. Canine Adenovirus
16. Oncolytic Adenovirus
17. Imaging Analysis
18. Adenoviral Vaccines - Cancer
19. Adenoviral Vaccines - Infectious Disease
20. Adenoviral Vaccines - COVID 19
21. Adenoviral Vectored Veterinary Vaccines
22. Utility of Adenoviral Vectors in Animal Models - CV Disease
23. Utility of Adenoviral Vectors in Animal Models - Pulmonary Disease
24. Utility of Adenoviral Vectors in Animal Models - Genetic Disease
25. Adenoviral Vectors for Gene Editing
26. Manufacturing and Upscaling
27. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms
3. Adenovirus Replication
4. Adenoviral Vector Construction I: Mammalian Systems
5. Adenoviral Vector Construction II: Bacterial Systems
6. Adenoviral Vector Packing Cell Lines
7. Purification of Adenovirus
8. Innate Immune Response to Adenovirus
9. Antibodies to Adenovirus
10. Methods to Mitigate Immune Response
11. Xenogenic Adenoviral Vectors as Vaccines
12. Adenoviral Vector Targeting
13. Helper-Dependent Adenovirus
14. Hybrid Adenoviral Vectors
15. Canine Adenovirus
16. Oncolytic Adenovirus
17. Imaging Analysis
18. Adenoviral Vaccines - Cancer
19. Adenoviral Vaccines - Infectious Disease
20. Adenoviral Vaccines - COVID 19
21. Adenoviral Vectored Veterinary Vaccines
22. Utility of Adenoviral Vectors in Animal Models - CV Disease
23. Utility of Adenoviral Vectors in Animal Models - Pulmonary Disease
24. Utility of Adenoviral Vectors in Animal Models - Genetic Disease
25. Adenoviral Vectors for Gene Editing
26. Manufacturing and Upscaling
27. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective
- No. of pages: 906
- Language: English
- Edition: 3
- Published: April 9, 2025
- Imprint: Academic Press
- Hardback ISBN: 9780323898218
- eBook ISBN: 9780323958141
DC
David T. Curiel
David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.
Affiliations and expertise
Washington University School of Medicine, St. Louis, MO, USAAP
Alan L. Parker
Affiliations and expertise
Professor of Translational Virotherapies, Head of Section of Solid Cancers, Division of Cancer and Genetics, University of Cardiff, UKRead Adenoviral Vectors for Gene Therapy on ScienceDirect